45 related articles for article (PubMed ID: 8616906)
1. Biotransformation of the platinum drug JM216 following oral administration to cancer patients.
Raynaud FI; Mistry P; Donaghue A; Poon GK; Kelland LR; Barnard CF; Murrer BA; Harrap KR
Cancer Chemother Pharmacol; 1996; 38(2):155-62. PubMed ID: 8616906
[TBL] [Abstract][Full Text] [Related]
2. Current Status of Novel Multifunctional Targeted Pt(IV) Compounds and Their Reductive Release Properties.
Xu L; Kong X; Li X; Zhang B; Deng Y; Wang J; Duan C; Zhang D; Liu W
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398498
[TBL] [Abstract][Full Text] [Related]
3. Metallo-Drugs in Cancer Therapy: Past, Present and Future.
Lucaciu RL; Hangan AC; Sevastre B; Oprean LS
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235023
[TBL] [Abstract][Full Text] [Related]
4. Metabolite Profiling in Anticancer Drug Development: A Systematic Review.
Muhamad N; Na-Bangchang K
Drug Des Devel Ther; 2020; 14():1401-1444. PubMed ID: 32308372
[TBL] [Abstract][Full Text] [Related]
5. A Dogma in Doubt: Hydrolysis of Equatorial Ligands of Pt
Kastner A; Poetsch I; Mayr J; Burda JV; Roller A; Heffeter P; Keppler BK; Kowol CR
Angew Chem Int Ed Engl; 2019 May; 58(22):7464-7469. PubMed ID: 30870571
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-targeted drug delivery.
Sharma A; Arambula JF; Koo S; Kumar R; Singh H; Sessler JL; Kim JS
Chem Soc Rev; 2019 Feb; 48(3):771-813. PubMed ID: 30575832
[TBL] [Abstract][Full Text] [Related]
7. The impact of whole human blood on the kinetic inertness of platinum(iv) prodrugs - an HPLC-ICP-MS study.
Theiner S; Grabarics M; Galvez L; Varbanov HP; Sommerfeld NS; Galanski MS; Keppler BK; Koellensperger G
Dalton Trans; 2018 Apr; 47(15):5252-5258. PubMed ID: 29560976
[TBL] [Abstract][Full Text] [Related]
8. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.
Johnstone TC; Suntharalingam K; Lippard SJ
Chem Rev; 2016 Mar; 116(5):3436-86. PubMed ID: 26865551
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application.
Theiner S; Varbanov HP; Galanski MS; Egger AE; Berger W; Heffeter P; Keppler BK
J Biol Inorg Chem; 2015 Jan; 20(1):89-99. PubMed ID: 25413442
[TBL] [Abstract][Full Text] [Related]
10. A novel class of bis- and tris-chelate diam(m)inebis(dicarboxylato)platinum(IV) complexes as potential anticancer prodrugs.
Varbanov HP; Göschl S; Heffeter P; Theiner S; Roller A; Jensen F; Jakupec MA; Berger W; Galanski MS; Keppler BK
J Med Chem; 2014 Aug; 57(15):6751-64. PubMed ID: 25032896
[TBL] [Abstract][Full Text] [Related]
11. Synthetic methods for the preparation of platinum anticancer complexes.
Wilson JJ; Lippard SJ
Chem Rev; 2014 Apr; 114(8):4470-95. PubMed ID: 24283498
[No Abstract] [Full Text] [Related]
12. Organic Anion Transporting Polypeptide 5A1 (OATP5A1) in Small Cell Lung Cancer (SCLC) Cells: Possible Involvement in Chemoresistance to Satraplatin.
Olszewski-Hamilton U; Svoboda M; Thalhammer T; Buxhofer-Ausch V; Geissler K; Hamilton G
Biomark Cancer; 2011; 3():31-40. PubMed ID: 24179389
[TBL] [Abstract][Full Text] [Related]
13. An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors.
Paola ED; Alonso S; Giuliani R; Calabrò F; D'Alessio A; Regine G; Cerbone L; Bianchi L; Mancuso A; Sperka S; Rozencweig M; Sternberg CN
Front Oncol; 2012; 2():175. PubMed ID: 23189269
[TBL] [Abstract][Full Text] [Related]
14. Can Satraplatin be hydrated before the reduction process occurs? The DFT computational study.
Bradáč O; Zimmermann T; Burda JV
J Mol Model; 2013 Nov; 19(11):4669-80. PubMed ID: 22643969
[TBL] [Abstract][Full Text] [Related]
15. The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates.
Marcus L; Murphy R; Fox E; McCully C; Cruz R; Warren KE; Meyer T; McNiff E; Balis FM; Widemann BC
Cancer Chemother Pharmacol; 2012 Jan; 69(1):247-52. PubMed ID: 21706317
[TBL] [Abstract][Full Text] [Related]
16. Anticancer activity of metal complexes: involvement of redox processes.
Jungwirth U; Kowol CR; Keppler BK; Hartinger CG; Berger W; Heffeter P
Antioxid Redox Signal; 2011 Aug; 15(4):1085-127. PubMed ID: 21275772
[TBL] [Abstract][Full Text] [Related]
17. Satraplatin: leading the new generation of oral platinum agents.
Bhargava A; Vaishampayan UN
Expert Opin Investig Drugs; 2009 Nov; 18(11):1787-97. PubMed ID: 19888874
[TBL] [Abstract][Full Text] [Related]
18. Satraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation.
McKeage MJ
Drugs; 2007; 67(6):859-69. PubMed ID: 17428104
[TBL] [Abstract][Full Text] [Related]
19. A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473).
Beale P; Judson I; O'Donnell A; Trigo J; Rees C; Raynaud F; Turner A; Simmons L; Etterley L
Br J Cancer; 2003 Apr; 88(7):1128-34. PubMed ID: 12671715
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of dauricine and identification of its main metabolites.
Chen S; Liu L; Yang Y; Dai Z; Zeng F
J Tongji Med Univ; 2000; 20(3):253-6. PubMed ID: 11215064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
